Circio Holding ASA · OSL:CRNA
Circio Holding ASA — Targovax — Solebury Trout European Biotech Investor Day 2019
17 slides from Circio Holding ASA's conference presentation, Aug 1, 2019
Slide 1: Targovax: Activating the immune system to fight cancer
Targovax the Activating immune Solebury Trout European Biotech Investor Day 2019 system to 1 August 2019 Company presentation fight cancer Øystein Soug, CEO August 2018
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of
Slide 3: Oncolytic viruses with key role in the future cancer therapy landscape
ONCOLYTIC VIRUSES WITH KEY ROLE IN THE FUTURE CANCER THERAPY LANDSCAPE Targovax focus Immune Immune activators modulators Oncolytic viruses Checkpoint inhibitors Surgery - Radio - Chemo Immune Targeted boosters therapy CAR-Ts, TCRs TKIs, PARPs, etc. 3
Slide 4: ONCOS oncolytic virus
Targovax focus ONCOS ONCOLYTIC VIRUS Adenovirus Serotype 5 o Genetically engineered to selectively infect cancer cells o Turns cold tumors hot Activates the o Single agent phase I trial completed immune system o Four ongoing clinical trials Triggers patient- specific immune responses o Combination w
Slide 5: ONCOS-102 clinical development program
ONCOS-102 CLINICAL DEVELOPMENT PROGRAM PD1 refractory melanoma o Combination with Keytruda Phase I o First cohort completed up to 21 patients Mesothelioma Phase I/II - o Combination with SoC chemo randomized o Enrolment completed Compassionate use Phase I trial 31 patients program 12 patients 115 pa
Slide 6: Ongoing ONCOS-102 Phase I in melanoma
ONGOING ONCOS-102 PHASE I IN MELANOMA PD1 refractory melanoma o Combination with Keytruda Phase I o First cohort completed up to 21 patients Mesothelioma Phase I/II - o Combination with SoC chemo randomized o Enrolment completed Compassionate use Phase I trial 31 patients program 12 patients 115 pat
Slide 7: Encouraging ORR and profound immune activation
ENCOURAGING ORR AND PROFOUND IMMUNE ACTIVATION ONCOS-102 melanoma highlights Test the hypothesis that ONCOS-102 will immune activate anti-PD1 refractory Trial objectives patients to respond to re-challenge with an anti-PD1 CPI 9 pts: advanced, unresectable melanoma with disease progression despite P
Slide 8: Complete response in 1 of 9 patients
COMPLETE RESPONSE IN 1 OF 9 PATIENTS following ONCOS-102 and Keytruda combination treatment Baseline Week 3 (from BL) Week 9 (from BL) Progression on Visible tumor regression CR after 3x ONCOS-102 Keytruda after 3x ONCOS-102 & 2x Keytruda Stage III Prior therapies: Surgery x 3 Yervoy, Tafinlar + Mek
Slide 9: ONCOS-102 clinical development program
ONCOS-102 CLINICAL DEVELOPMENT PROGRAM PD1 refractory melanoma o Combination with Keytruda Phase I o First cohort completed up to 21 patients Mesothelioma Phase I/II - o Combination with SoC chemo randomized o Enrolment completed Compassionate use Phase I trial 31 patients program 12 patients 115 pa
Slide 10: CD8+ T-cell infiltration correlates with survival
Phase I single agent proof-of-concept CD8+ T-CELL INFILTRATION CORRELATES WITH SURVIVAL Fold-change CD8+ T-cell count vs. survival r = 0.75 p = 0.005 Case examples: 10,000 CD8+ fold-change from baseline #1 – Ovarian cancer: failed on 5 types of chemo 1,000 o >1,000-fold increase in CD8+ T-cell infil
Slide 11: ONCOS-102 monotherapy in mesothelioma
ONCOS-102 MONOTHERAPY IN MESOTHELIOMA turning cold tumors hot CD8+ T-cells in tumor CD4+ T-cells in tumor PD-L1 positive tumor cells Tumor biopsy staining Fold change % of total Mesothelioma – Phase I, patient 14 6.5 19.5 130x 16x 1 1.2 Baseline Week 5 Baseline Week 5 Baseline Week 5 Mesothelioma –
Slide 12: Ongoing ONCOS-102 Phase II in mesothelioma
ONGOING ONCOS-102 PHASE II IN MESOTHELIOMA PD1 refractory melanoma o Combination with Keytruda Phase I o First cohort completed up to 21 patients Mesothelioma Phase I/II - o Combination with SoC chemo randomized o Enrolment completed Compassionate use Phase I trial 31 patients program 12 patients 11
Slide 13: Phase I/II study design in combination with SoC
ONCOS-102 in malignant pleural mesothelioma PHASE I/II STUDY DESIGN IN COMBINATION WITH SoC Six patient safety Enrollment lead-in reported completed May May 2018 2019 Experimental group (n=14) ONCOS-102 plus Patient population Safety lead-in (n=6) Non-randomized Randomized SoC (6 cycles) Advanced ma
Slide 14: Mesothelioma ONCOS-102 path-to-market
MESOTHELIOMA ONCOS-102 PATH-TO-MARKET Rationale for ONCOS-102 go-to-market strategy in mesothelioma: Become frontline therapy Orphan Drug Designation Limited competition o Preclinical data and phase o High unmet medical need; o CPIs are potential I results indicate activity in orphan drug designatio
Slide 15: Rich near-term news flow
RICH NEAR-TERM NEWS FLOW ONCOS program pipeline overview Product Preclinical Phase I Phase II Phase III Next expected event candidate Mesothelioma New year 2019-20 Combination w/ pemetrexed/cisplatin Randomized data 1H 2020 Melanoma Interim data Combination w/Keytruda second cohort ONCOS-102 Periton
Slide 16: Next generation ONCOS viruses: double transgenes and distinct modes of action
NEXT GENERATION ONCOS VIRUSES: DOUBLE TRANSGENES AND DISTINCT MODE OF ACTIONS Target tumors Development status ONCOS-210 Inhibition of tumor growth o Highly invasive or o In vitro testing completed and vascularization metabolic tumors o First in vivo testing completed ONCOS-211 Counteract immune- o
Slide 17: Activating the patient's immune system to fight cancer
ACTIVATING THE PATIENT`S IMMUNE SYSTEM to fight cancer Clinically proven Rich news flow Innovative pipeline One of the furthest developed Four ongoing trials Next generation oncolytic viruses viruses in testing Several upcoming data Strong single agent data readouts over the next 6-18 months Encoura
Targovax — Solebury Trout European Biotech Investor Day 2019 on 6ix